1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial
Interim analysis
Interim
DOI:
10.1016/j.annonc.2024.08.1315
Publication Date:
2024-09-17T20:27:33Z
AUTHORS (3)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....